News
Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...
The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety ...
The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...
Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...
After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...
S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.
The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback